Hennion & Walsh Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Hennion & Walsh Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,888	Closed	-$43.7K	–	849
2023 Q3	$43.7K	Sell	4,888 -964	-16%	-$9.28K	﹤0.01%	797
2023 Q2	$50K	Buy	5,852 +61	+1%	+$650	﹤0.01%	796
2023 Q1	$61K	Sell	5,791 -136	-2%	-$4.12K	﹤0.01%	769
2022 Q4	$201K	Sell	5,927 -8,943	-60%	-$433K	0.01%	731
2022 Q3	$714K	Sell	14,870 -715	-5%	-$42.5K	0.05%	405
2022 Q2	$888K	Sell	15,585 -6,369	-29%	-$402K	0.06%	345
2022 Q1	$1.77M	Buy	21,954 +1,312	+6%	+$194K	0.09%	239
2021 Q4	$4.18M	Buy	20,642 +1,668	+9%	+$362K	0.21%	131
2021 Q3	$5.11M	Sell	18,974 -616	-3%	-$148K	0.27%	96
2021 Q2	$5.04M	Buy	19,590 +1,943	+11%	+$538K	0.27%	91
2021 Q1	$5.29M	Buy	+17,647	New	+$5.49M	0.32%	78

Other funds holding NKTR

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Hennion & Walsh Asset Management's NKTR Position: Q4 2023 in Review

Hennion & Walsh Asset Management sold out of Nektar Therapeutics (NKTR) in Q4 2023, closing a stake of 4,888 shares — an estimated $43.7K sold.

Hennion & Walsh Asset Management first reported a position in NKTR in Q1 2021 and held it in 11 quarters. The position peaked at $5.29M in Q1 2021. 125 funds tracked by Wall St. Rank hold NKTR as of Q4 2023.

Hennion & Walsh Asset Management reported no remaining Nektar Therapeutics position as of Q4 2023 after selling out during the quarter.
Hennion & Walsh Asset Management sold 4,888 Nektar Therapeutics shares in Q4 2023, an estimated $43.7K.
Hennion & Walsh Asset Management first reported a position in Nektar Therapeutics in Q1 2021 and held it in 11 quarters.
Hennion & Walsh Asset Management's Nektar Therapeutics position peaked at $5.29M in Q1 2021.
125 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2023, filed 10 Jan 2024.